JP Morgan Chase
CUE icon

JP Morgan Chase’s Cue Biopharma CUE Stock Holding History

JP Morgan Chase’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-440
Closed -$33K – 6512
2022
Q2 		$33K Hold
440
– – ﹤0.01% 5771
2022
Q1 		$64K Hold
440
– – ﹤0.01% 5696
2021
Q4 		$149K Buy
+440
New +$170K ﹤0.01% 5499

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

JP Morgan Chase's CUE Position: Q2 2026 in Review

JP Morgan Chase opened a new position in Cue Biopharma (CUE) in Q2 2026: 163 shares worth $4.96K. The stake represents ﹤0.01% of the portfolio and ranks #7071 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in CUE as recently as Q3 2025.

JP Morgan Chase first reported a position in CUE in Q1 2018 and has held it in 32 quarters since. The position peaked at $229K in Q2 2020. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • JP Morgan Chase held 163 shares of Cue Biopharma worth $4.96K as of Q2 2026.
  • Cue Biopharma was a new JP Morgan Chase position in Q2 2026.
  • Cue Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7071 holding.
  • JP Morgan Chase first reported a position in Cue Biopharma in Q1 2018 and has held it in 32 quarters since.
  • JP Morgan Chase's Cue Biopharma position peaked at $229K in Q2 2020.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.